RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

By sjmartinez • February 2, 2024

Nishino K, Shih JY, Nakagawa K, Reck M, Garon EB, Carlsen M, Matsui T, Visseren-Grul C, Nadal E. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants. JTO Clin Res Rep. 2023 Dec 19;5(2):100624. doi: 10.1016/j.jtocrr.2023.100624. PMID: 38304857; PMCID: PMC10832259.

Tags: Carcinoma, EGFR exon 19 deletion variant, Hematology/Oncology, Non–small cell lung, Publications, ramucirumab, targeted therapy, VEGFR inhibition

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer

Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig M, Maxwell KN, Schoen MW. Tumor[...]

B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism

Larios R, Hossain MB, Brown R, Jeyachandran AV, Abu AE, Zaiss AK, Ramirez CM, Kamata M, Cole S, Wu TT, Dorshkind K, Arumugaswami V, Morizono[...]

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB,[...]